Our lead product, masitinib, is a tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through more than 20 indications in oncology, inflammatory diseases, and central nervous system diseases.
AB Science has its headquarters in Paris and is listed on Euronext Paris (ticker: AB). For more information, please visit our website: www.ab-science.com
For more information, please contact:
AB Science
Christophe Vivet
Investor Relations
+33 1 47 63 27 98
Attachment
PR in English
Our programs target only diseases with high unmet medical needs, often lethal with short-term survival or rare or refractory to previous lines of treatment.
AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is being developed in human medicine in oncology, neurological diseases, inflammatory diseases, and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).
Further information is available on AB Science’s website: www.ab-science.com.
Forward-looking Statements – AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions, and expectations regarding financial results, events, operations, future services, product development, and their potential or future performance.
These forward-looking statements can often be identified by the words expect, anticipate, believe, intend, estimate, or plan as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced, or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect the marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.
For additional information, please contact:
AB Science
Financial Communication & Media Relations
Sickle Cell Patent EPO vENG VF (NYSE:)
Source: AB Science – rewrite to a total of 500-750 words. Then translate to B1 English and retrieve only the translated text. Keep HTML tags. Don’t echo me back. Don’t echo the sent text. Only provide English text.